2023-11-15 15:49:28
From October 20 to 24, 2023, the ESMO (European Society for Medical Oncology) congress took place in Madrid. It is the unmissable meeting place for European oncology researchers. Many study groups present their work and the evolution of their research. With more than 25,000 oncology professionals from more than 160 countries around the world. The aim is to improve the overall care of patients suffering from malignant diseases. This year, the research carried out by the French-speaking Federation of Digestive Cancerology (FFCD) has been recognized and obtained validation. The care protocol for patients with cancer of the stomach and esophagogastric junction has changed thanks to the studies of French-speaking researchers.
What is the French-speaking Federation of Digestive Cancerology?
The French-speaking Federation of Digestive Cancerology (FFCD) is a non-profit association. She is actively involved in digestive cancer research, coordinating and leading clinical and translational studies. These studies aim to improve treatment protocols for patients with cancers of the digestive system.
The organization covers all locations of the digestive system, including the rarest forms of cancer. The research carried out is organized around therapeutic management with new administration strategies, surgery and radiotherapy. In order to’study all areas of improvement and care.
The FFCD collaborates with 150 health establishments in France, including university hospitals, hospital centers, cancer centers (CLCC) and private clinics. The federation publishes all the results of its clinical research on its site as well as in international medical journals, whether positive or negative. This approach contributes to the dissemination of knowledge and the improvement of care in digestive oncology.
The new FFCD standard for treating stomach cancer
Fédération Francophone de Cancérologie Digestive (FFCD) presented its research at the 2023 ESMO congress. Its studies demonstrated the effectiveness of a new treatment protocol for people with cancer of the stomach and esophageal junction.
This type of cancer develops at the junction between the stomach and the end of the esophagus. The processing standard applied by the FFCD concerns HER2 negative metastatic cancer. Which means that metastatic activity (cancer cells) is low.
The FFDC presented its comparison study between Folfox (protocol commonly used until now) and Tfox. The tests were carried out on 506 patients between December 2016 and December 2022. They demonstrate an improvement thanks to the tri-chemotherapy protocol with Tfox.
The difference between FolFox and Tfox to fight stomach cancer
FolFox is commonly used in the management of gastric and esophageal junction cancer. It is one of the therapeutic standards in first line chemotherapy. FolFox combines several medications: fluorouracil, oxaliplatin, leucovorin, Xeloda (capecitabine), all administered intravenously.
TFOX is a chemotherapy regimen that uses oxaliplatin, docetaxel, and capecitabine (Xeloda) as the main drugs. It does not contain fluorouracil or leucovorin.
The tests carried out compare:
- progression survival (PFS), a long PFS, means that the treatment slows the progression of the cancer.
- the objective response rate (OR), which is the percentage of patients whose tumors shrink in size or disappear in response to treatment.
- overall survival (OS), a longer overall survival means that the treatment helped prolong the lives of patients.
The FFDC noted positive responses to treatment with Tfox, with a median OS of more than 15 months. So triple therapy (by Tfox) might be established for advanced cases of cancer. Much research is being carried out by scientists, doctors and specialists around the world. They make it possible to improve the diagnosis and treatment of patients.
Sources
– HECTOR Hosting of clinical and therapeutic trials in regional oncology, hector-ssais-cliniques.fr. Accessed November 1, 2023.
– SNFGE French National Society of Gastroenterology: Stomach cancer www.snfge.org. Accessed November 1, 2023.
1700072900
#protocol #stomach #cancer
